Early clinical indicators of acute kidney injury caused by administering high-dose methotrexate therapy to juvenile pigs

Early identification of compromised renal clearance caused by high-dose methotrexate (HDMTX) is essential for initiating timely interventions that can reduce acute kidney injury and MTX-induced systemic toxicity.We induced acute kidney injury (AKI) by infusing 42 juvenile pigs with 4 g/kg (80 g/m2) of MTX over 4 hours without high-volume alkalinizing hydration therapy. Concentrations of serum creatinine and MTX were measured at 15 time points up to 148 hours, with 10 samples collected during the first 24 hours after the start of the HDMTX infusion.During the first 28 hours, 81% of the pigs had increases in the concentrations of serum creatinine in one or more samples indicative of AKI (i.e., > 0.3g/dL increase). A rate of plasma MTX clearance of less than 90% during the initial 4 hours after the HDMTX infusion and a total serum creatinine increase at 6 and 8 hours after starting the infusion greater than 0.3 g/dL were predictive of AKI at 28 hours (p < 0.05 and p < 0.001, respectively). At conclusion of the infusion, pigs with a creatinine concentration more than 0.3 g/dL higher than baseline or serum MTX greater than 5,000 μmol/L had an increased risk of severe AKI.Our findings suggest that serum samples collected at conclusion and shortly after HDMTX infusion can be used to predict impending AKI. The pig model can be used to identify biological, environmental, and iatrogenic risk factors for HDMTX-induced AKI and to evaluate interventions to preserve renal functions, minimize acute kidney injury, and reduce systemic toxicity.

[1]  F. Zanaty,et al.  Evaluation of kidney dysfunction in childhood cancer survivors , 2022, Pediatric Research.

[2]  Shruti Gupta,et al.  Conventional Chemotherapy Nephrotoxicity. , 2021, Advances in chronic kidney disease.

[3]  H. Katzenstein,et al.  Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia. , 2020, Journal of pediatric hematology/oncology.

[4]  M. Perazella Drug-induced acute kidney injury: diverse mechanisms of tubular injury. , 2019, Current opinion in critical care.

[5]  A. Brandoni,et al.  Time evolution of methotrexate‐induced kidney injury: A comparative study between different biomarkers of renal damage in rats , 2019, Clinical and experimental pharmacology & physiology.

[6]  Q. Guo,et al.  Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia , 2019, Cancer management and research.

[7]  A. Vinks,et al.  Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib , 2019, Pediatric blood & cancer.

[8]  C. Ryan,et al.  Safety and efficacy of high‐dose methotrexate for osteosarcoma in adolescents compared with young adults , 2018, Cancer medicine.

[9]  S. Piperno-Neumann,et al.  A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High‐Dose Methotrexate: Data From the OS2006/Sarcoma‐09 Trial , 2018, Journal of clinical pharmacology.

[10]  S. Hilsenbeck,et al.  A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities , 2018, Cancer Chemotherapy and Pharmacology.

[11]  Jing Tian,et al.  Renal Function and Plasma Methotrexate Concentrations Predict Toxicities in Adults Receiving High-Dose Methotrexate , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[12]  T. Muthukumar,et al.  Management of Patients with Acute Methotrexate Nephrotoxicity with High‐Dose Leucovorin , 2018, Pharmacotherapy.

[13]  K. Yu,et al.  Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma. , 2018, Journal of pharmaceutical sciences.

[14]  Tao-tao Liu,et al.  Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia , 2018, Chemotherapy.

[15]  C. Rioufol,et al.  Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences? , 2018, Hematological oncology.

[16]  A. Rule,et al.  Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function , 2018, Case reports in hematology.

[17]  P. Sangild,et al.  Animal models of chemotherapy-induced mucositis: translational relevance and challenges. , 2018, American journal of physiology. Gastrointestinal and liver physiology.

[18]  Victor G. Puelles,et al.  Development of the Human Fetal Kidney from Mid to Late Gestation in Male and Female Infants , 2017, EBioMedicine.

[19]  A. Bleyer,et al.  Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance , 2017, The oncologist.

[20]  A. Rule,et al.  Structural and Functional Changes in Human Kidneys with Healthy Aging. , 2017, Journal of the American Society of Nephrology : JASN.

[21]  Manupat Lohitnavy,et al.  A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans , 2017, 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[22]  K. Schmiegelow,et al.  Delayed elimination of high‐dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia , 2017, Pediatric blood & cancer.

[23]  M. Mrug,et al.  Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy , 2017, SAGE open medical case reports.

[24]  S. Choquet,et al.  Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance , 2017, Pharmacological research.

[25]  M. Joannidis,et al.  Acute kidney injury 2016: diagnosis and diagnostic workup , 2016, Critical Care.

[26]  Z. Özdemir,et al.  The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate , 2016, International journal of pediatrics & adolescent medicine.

[27]  A. Arany,et al.  Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma , 2016, Oncotarget.

[28]  C. Pui,et al.  Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.

[29]  G. Phillips,et al.  Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[30]  L. Silverman,et al.  Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. , 2016, The Lancet. Oncology.

[31]  J. Lingeman,et al.  Intraluminal measurement of papillary duct urine pH, in vivo: a pilot study in the swine kidney , 2016, Urolithiasis.

[32]  A. P. Garneau,et al.  Acute Methotrexate-Induced Crystal Nephropathy. , 2015, The New England journal of medicine.

[33]  S. Vishnubhatla,et al.  Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate , 2015, Pediatric hematology and oncology.

[34]  T. Key,et al.  Plasma concentrations and intakes of amino acids in male meat-eaters, fish-eaters, vegetarians and vegans: a cross-sectional analysis in the EPIC-Oxford cohort , 2015, European Journal of Clinical Nutrition.

[35]  S. Ragab,et al.  Evaluation of serum and urine fetuin-A levels in children with acute lymphoblastic leukemia during and after high-dose methotrexate therapy: Relation to toxicity , 2015, Hematology.

[36]  K. Jahnukainen,et al.  Assessment of renal function during high‐dose methotrexate treatment in children with acute lymphoblastic leukemia , 2014, Pediatric blood & cancer.

[37]  Asha B. Pillai,et al.  The Weaned Pig as a Model for Doxorubicin-Induced Mucositis , 2014, Chemotherapy.

[38]  M. Perazella,et al.  Crystalline-induced kidney disease: a case for urine microscopy , 2014, Clinical kidney journal.

[39]  P. Wehner,et al.  Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high‐dose methotrexate infusions: A prospectively randomized cross‐over study , 2014, Pediatric blood & cancer.

[40]  P. van Eyken,et al.  “Physiological” renal regenerating medicine in VLBW preterm infants: could a dream come true? , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[41]  M. Relling,et al.  Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients , 2012, Cancer.

[42]  S. Mallipattu,et al.  Methotrexate in the urine. , 2011, Kidney International.

[43]  S. Raimondi,et al.  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Victor G Puelles,et al.  Glomerular number and size variability and risk for kidney disease , 2011, Current opinion in nephrology and hypertension.

[45]  A. Narla,et al.  Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity. , 2010, Clinical chemistry.

[46]  C. Petito,et al.  Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model , 2010, Journal of Neuro-Oncology.

[47]  R. Bellomo,et al.  Renal plasma flow and glomerular filtration rate duringacute kidney injury in man , 2010, Renal Failure.

[48]  O. Mir,et al.  Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma , 2010, Cancer Chemotherapy and Pharmacology.

[49]  O. van Tellingen,et al.  Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo , 2009, Molecular Cancer Therapeutics.

[50]  H. Colom,et al.  Population Pharmacokinetics of High-Dose Methotrexate After Intravenous Administration in Pediatric Patients With Osteosarcoma , 2009, Therapeutic drug monitoring.

[51]  T. Salmi,et al.  Long‐term follow‐up of renal function after high‐dose methotrexate treatment in children , 2008, Pediatric blood & cancer.

[52]  P. Nathan,et al.  Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P , 2006, Leukemia & lymphoma.

[53]  Ş. Olgar,et al.  Evaluation of kidney damage in patients with acute lymphoblastic leukemia in long‐term follow‐up: Value of renal scan , 2004, American journal of hematology.

[54]  F. Zintl,et al.  Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. , 2003, Medical and pediatric oncology.

[55]  M. Jarfelt,et al.  High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL) , 2003, Cancer Chemotherapy and Pharmacology.

[56]  A. Prémaud,et al.  An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. , 2002, Toxicology and applied pharmacology.

[57]  A. Takeuchi,et al.  Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. , 2001, Kidney international.

[58]  B. Lindqvist,et al.  Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. , 2000, Leukemia research.

[59]  P. Adamson,et al.  Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. , 1999, Clinical chemistry.

[60]  S. Garwicz,et al.  High‐dose methotrexate causes short‐term suppression of growth in rabbits , 1995, Acta paediatrica.

[61]  J. Borsi,et al.  A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia , 1987, Cancer.

[62]  B. Chabner,et al.  Dose-dependent metabolism of methotrexate in man and rhesus monkeys. , 1977, Cancer treatment reports.

[63]  P. Creaven,et al.  Methotrexate in Liver and Bile after Intravenous Dosage in Man , 1973, British Journal of Cancer.

[64]  R. Mathôt,et al.  Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature. , 2018, The Netherlands journal of medicine.

[65]  Xiaohui Chen,et al.  Simultaneous Determination of Five Specific and Sensitive Nephrotoxicity Biomarkers in Serum and Urine Samples of Four Drug-Induced Kidney Injury Models. , 2017, Journal of chromatographic science.

[66]  L. Chawla,et al.  Biomarkers of renal function, which and when? , 2015, Clinica chimica acta; international journal of clinical chemistry.

[67]  Yongmin Tang,et al.  Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies , 2013, Cancer Chemotherapy and Pharmacology.

[68]  J. Lukas,et al.  Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukaemia , 2006, Clinical pharmacokinetics.

[69]  S. Jacobsen,et al.  Effect of urine pH and flow on renal clearance of methotrexate , 2004, European Journal of Clinical Pharmacology.

[70]  J. Chládek,et al.  [Renal excretion of methotrexate in an in vivo model in minipigs]. , 2000, Acta medica (Hradec Kralove). Supplementum.

[71]  J. Borsi,et al.  Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology. , 1990, Pediatric hematology and oncology.

[72]  G. Koren The Nephrotoxic Potential of Drugs and Chemicals Pharmacological Basis and Clinical Relevance , 1989, Medical toxicology and adverse drug experience.